Group 1 - Jinbo Biological has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Biological post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan designated for this project and the remaining 850 million yuan for working capital [2] Group 2 - Yangshengtang's involvement is expected to enhance Jinbo Biological's core competitiveness and innovation capabilities, providing strategic resources for market expansion and sales performance improvement [3] - In addition to Jinbo Biological's developments, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic plans to use the funds raised from the convertible bonds to supplement working capital, thereby alleviating financial pressure and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated as follows: 1.15 billion yuan for the development of a humanized collagen FAST database and product development platform, and 850 million yuan for working capital [2] Group 2 - The collaboration with Yangshengtang is expected to enhance Jinbo Bio's core competitiveness and innovation capabilities, as well as improve market expansion and sales performance [3] - In addition to Jinbo Bio's targeted stock issuance, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic's convertible bonds will be used entirely for working capital, addressing the company's funding needs and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has announced a private placement of shares, which has been accepted by the Beijing Stock Exchange, aiming to raise up to 2 billion yuan by issuing no more than 7.1757 million shares [1][2] - The strategic investor for this placement is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan dedicated to this project, enhancing the company's competitiveness in various medical fields [2][3] Group 2 - The private placement represents the largest scale of financing through a private placement on the Beijing Stock Exchange this year [2] - Jinbo Bio's collaboration with Yangshengtang is expected to bring advanced technological resources, enhancing core competitiveness and innovation capabilities, as well as improving market channels and brand resources [3] - Meanwhile, Wantong Hydraulic has received approval for a private convertible bond issuance, aiming to raise up to 150 million yuan to support its liquidity needs [4][5]